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of quantitative TEL/AML1 results and clinical outcome yield interesting preliminary findings. First, normalized TEL/AML1 values at diagnosis and relapse were always above 290. Even if the normalized values did not reflect the percentage of BM blasts (all the samples tested contained more then 90% of blasts after Ficoll enrichment), it should be possible to establish a threshold value corresponding to the level of morphologically detectable disease. Second, at the time of CR (day 35-45), all the patients had a reduction in TEL/AML1 values of at least two logs. Interestingly, the highest values were found in patients UPN3 and UPN4 who subsequently relapsed. Furthermore these patients developed detectable and quantifiable disease 3 to 5 months after entering the first CR, whereas patients UPN1 and UPN2 had TEL/AML1 below the quantitation limit. Patients UPN3 and UPN4 were consistently MRL positive.
We have shown that our RQ-RT-PCR assay can be used to calculate a slope of disease response to therapy for each patient. Thus, it might be possible to compare directly the relative efficacy of treatment regimens given to patients in different institutions, and therapy could conceivably be adapted to the individual response. The high efficiency and throughput of real-time PCR, as well as the absence of post-PCR manipulations, make Taqman methodology eminently suitable for routine large-scale application and an inter-laboratories standardization.
The common deletion 657del5 in the Nibrin gene is not a major risk factor for B or T cell non-Hodgkin lymphoma in a pediatric population TO 
THE EDITOR
Nijmegen breakage syndrome (NBS, MIM #251260), an autosomal recessive chromosome breakage disorder, is caused by mutations in the gene encoding Nibrin, a DNA double-strand repair protein, which is part of the RAD 50 protein complex. 1 Patients are characterised by microcephalus and hypoplasia of the mandible resulting in a typical craniofacial dysmorphy with a 'bird-like face', growth retardation, pigment anomalies, mild to moderate mental retardation, 2 and they suffer from humoral and cellular immunodeficiency. Lymphocytes are hypersensitive to irradiation and arrest preferentially in G2 phase. Chromosomal studies in NBS patients show somatic structural aberrations and multiple rearrangements, favouring chromosome 7 and chromosome 14. Subsequently, patients are predisposed to malignancies with a tendency to develop non-Hodgkin lymphomas (NHL) at a young age. To date, 6 truncating mutations in the Nibrin gene have been identified. Five mutations are private to single families only, but a single 5 bp deletion (657del5) in exon 6 is by far the most prevalent one. 3 The predisposition of NBS patients to develop lymphoid malignancies at a young age raises the question whether heterozygosity for the common Nibrin gene mutation 657del5 might also play a role in the development NHL in otherwise unaffected children.
Our study was initiated by the case of a boy who developed a second B cell NHL. By clinical signs and cytogenetic findings we diagnosed NBS. The diagnosis was confirmed by cell cycle analysis, and identification of the homozygous deletion 657del5 by PCR of a 90 bp fragment, subsequent electrophoresis and direct sequencing. primer sequences were as follows: 5Ј-TAA CAT AAT TAC CTG TTT GGC-3Ј (sense), 5Ј-AAT GTT GAT CTG TCA GGA C-3Ј (antisense). The annealing temperature was 58°C.
The same molecular techniques were applied for analyzing a total of 55 German children with B-NHL (n = 29), T-NHL (n = 25), and undifferentiated NHL (n = 1) who were treated, either according to the German NHL-BFM 95 study protocol (B-NHL), or to the COALL 97 study protocol (T-NHL), respectively. Additionally, seven cell lines (three B-NHL, four T-NHL) were screened.
The common deletion 657del5 was detected only in our homozygous NBS patient and in his heterozygous healthy parents and his healthy brother, but not in our additional 55 children with NHL. Whereas heterozygosity for 657del5 in an Eastern European population has been estimated as 1:150, 4 screening of a German control population of adult women, revealed a frequency of only 1:866.
5 If heterozygosity for 657del5 were to constitute a major risk factor for the manifestation of lymphoma, heterozygous individuals would be expected to accumulate in a cohort of children with NHL. Our negative screening results exclude a major impact of by far the most common 657del5 NBS mutation on the manifestation of NHL in children without NBS, however, the number of recruited individuals does not allow excluding a smaller contributing effect.
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Department Overexpression of heat shock protein 60 and the survival of blast in acute myeloid leukemia after induction therapy TO THE EDITOR Many patients with acute myeloid leukemia (AML) who achieved complete remission (CR) relapse with their disease. We have investigated bone marrow aspirates obtained from AML patients using preparations fixed in 95% ethanol solution and stained with Papanicolaou method. We reported that the blasts (cells with a nucleolus/or nucleoli) at diagnosis were classified into blasts with a clear halo around the nucleolus (BCHN) and non-BCHN blasts, and the patients who had BCHNs at the end of the induction therapy invariably relapsed. 1 The persisting BCHNs at the end of the induction therapy were similar to those of BCHNs at diagnosis. 1 Several investigators reported that an exposure of tumor cells to antitumor drugs selectively induced synthesis of heat shock protein (HSP).
2 Induction of HSP correlated with development of a transient state of cross-tolerance to several cytotoxic agents. 2 To clarify the role of HSP in the survival of BCHN and blasts (BCHNs + non-BCHNs) after the induction therapy, we compared the levels of antibodies staining for four types of HSPs (27, 60, 70, and 90) in 58 newly diagnosed patients with AML (M1, Figure 1 Leukemic blasts, staining for HSP 60 (a case in group 1, both ×500). Disap of BCHN, disappearance of BCHN at the end of induction therapy; CR, achievement of the first complete remission.
12; M2, 24; M3, 4; M4, 10; M5, 5; M6, 3) at diagnosis and those at the end of the induction therapy. Thirty-seven patients were treated with BHAC-DMP (N 4 -behenoyl-1-␤-D-arabinofuranosyl-cytosine + daunorubicin (DNR) + 6-mercaptopurine + prednisolone), 10 patients were with cytosine arabinoside (Ara-C) + DNR and 11 patients were with Ara-C + Idarubicin. Two patients underwent bone marrow transplantation, and three died of infection. The other patients received consolidation and maintenance therapy. Bone marrow aspirates were directly smeared on glass slides, air-dried, fixed with methanol and stained with Pappenheim method. Papanicolaou-stained smears were prepared by commonly used preparatory techniques. 1 Immunocytochemical examination was performed with the DAKO EnVision system (Dakopatts, Glostrup, Denmark) using monoclonal anti-HSP27 ( 
